The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Back in now the SP has come down to a decent level
Strong well run company Leader in it's field 55p looks a good entry
Can't seem to crawl over the line!
mostly buys to-day Should rise above 60p Good blue day
not got a clue as to why the share price is slipping back BUT sold my shares in ASSURA GROUP about 10 days ago for a price just shy of 60p and made a rather nice profit and if the share price continue to fall i may be tempted to jump back in and buy some more shares in this excellent company.
Was going along quite nicely now slipping back. Any thoughts?
hard to say if you've missed the boat BUT if you do decide to buy shares they pay out a decent dividend 4 times a year
i have been watching AGR for some time since pre 50p. Does anyone think i have missed the boat? look really solid numbers.
Buying on an ex-dividend day, bodes well.
Renewed take over rumours?
Heavy buying ..... share price moving ahead...... Assura well under the radar.... at the moment!
A company with mega institutional backing!
One of the best investments I've ever made! Ethical well run company! Cares and rewards its shareholders!
Sorry chaps wrong board!!
Stagecoach will loose out on future bids because of Brian Souters support for independance They don't like it up em Captain. No mandate Tory boys!!!!!!!
Buy MXF This deal will be dumped !
I've held these for months. They haven't done a thing, so I decided to sell. Two hours later, there's an RNS about a possible takeover. Typical of my luck!
on this one. It's like an old US wild west town :-) Anything coming up?
Assura Group Ltd. (AGR) Director name: Mr David H Richardson Amount purchased: 85,811 @ 34.90p Value: £29,948
Only read a little about assura but they seem to be turning round after having a disasterous management. I.C have tipped them and there is a lot of blues recently. Looks like a slow burner.Any thoughts The board here is very quiet
Assura Group: Oriel Securities starts with an add recommendation. Espirito Santo moves target price from 37p to 37.50p, buy recommendation unchanged.
Investors are instead probably waiting for a track record of earnings and dividends to emerge after Assura's turnaround. But Mr Roberts has already promised quarterly dividends amounting to 1.14p a share for this year. It's worth buying now while the safe-haven story remains reasonably cheap..........BUT ALWAYS DYOR
Another criticism concerns its dividend yield, which is lower than that of peers. But that's because PHP and MedicX pay their dividends out of capital as well as out of cash profits. Strip out capital gains on properties and Assura's earnings yield (earnings per share divided by the share price) is actually the highest of the three. What this means is that Assura's dividends have room to grow organically. Contrast that with MedicX and PHP, who announce a new acquisition or development almost every week in a frantic bid to improve their dividend cover. Moreover, Assura's NAV will not be eroded by the payouts - as has been the case in the other players' recent results. A more valid criticism is that Assura has too much debt, with a loan-to-value ratio of 64 per cent. But the company's cost of borrowing, at 5.3 per cent, is still lower than the rental yield of its portfolio (5.9 per cent), so the debt does boost earnings. And its peers also have high loan-to-value ratios; debt cannot be the reason why Assura's shares trade at a discount.
The most obvious problem with Assura is its track record, and a glance at recent full-year results shows just how unstable profits have been. But Assura's results have for years been marred by a disastrous diversification into healthcare services and this business has since been sold to Richard Branson's Virgin Group and the management team responsible for the strategy ousted. That leaves the original property business, which itself has a good track record, largely intact. The new chief executive, Graham Roberts, who used to be British Land's finance director, is determined to make a clean break, which explains the hefty write-downs scarring this year's results. "Goodwill has no place on a property company's balance sheet," he says. He has just appointed a new finance director, Jonathan Murphy, who used to run Brooks Macdonald - very successfully judging by the wealth manager's share price growth.
Doctors' surgeries are about as safe as property investments come. NHS demand has nothing to do with the wider economy and is gradually growing with the ageing population and the fashion for treating patients at GP surgeries. Supply matches demand precisely - with only one tenant in the market, there's no speculative development. Accordingly, rents are not cyclical, as in other commercial property markets and instead grow with development costs. The only problem with this asset class is that it tends to come at a price. Those who followed our tips on Primary Health Properties (PHP) and the MedicX Fund (MXF) last year are sitting on substantial profits - so much so that the shares, never cheap, now look distinctly expensive (we have recently downgraded recommendations on both to hold). Meanwhile, shares in a third GP landlord - Assura (AGR) - trade at a 10 per cent discount to the end-March adjusted net asset value (NAV) and an even greater discount to that of their peers (see table). There are reasons for this but, on balance, Assura deserves to be re-rated.